Laurus Labs Limited (LAURUSLABS.NS) fair value

ACCE thesis

Laurus Labs makes active pharmaceutical ingredients and finished dosage forms, with a large share of its output in antiretroviral and oncology molecules sold to generic and innovator customers, plus a growing custom synthesis and contract development book. The moat is process chemistry at scale: multi-step API routes that are costly for competitors to replicate, backed by regulatory filings that lock in customers for years once a product is qualified. The growth case rests on the company moving further up the value chain into formulations and integrated oncology supply, which lifts revenue per unit and supports a 59.4% gross margin and 25.4% operating margin. Revenue is growing 29.1%, and at 66.8x forward earnings against 99.0x trailing, the market is pricing in a meaningful step-up in earnings that the coming year's results will need to confirm. The valuation leaves little room for execution slips in capacity commissioning or regulatory approvals, so the case is worth a deeper look mainly on whether the margin trajectory holds as the mix shifts.